Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...

As the rollout of its recently launched pulmonary arterial hypertension (PAH) drug Winrevair ramps up, Merck is continuing ...

Merck, which previously predicted 2024 sales between 20.7 billion ... is the world’s largest multimedia news provider, ...

Merck & Co has entered into an exclusive global license to develop, manufacture and commercialize LM-299 from China-based ...

Merck, which previously predicted 2024 sales of between 20. ... useful and valuable Life Sciences service that brings ...

After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...

Bindra and Herzon will also remain as consultants for Merck. According to Bindra, the Modifi Bio team met with Merck in ...

Merck , known as MSD outside of the United States and Canada, and LaNova Medicines Ltd. (LaNova), a privately held clinical-stage biotechnology company, today announced that Merck has entered into an ...

Merck made an after-tax profit of 812 million euros compared ... We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

Each year, 500 to 1,000 people in the U.S. are diagnosed with pulmonary arterial hypertension (PAH), a progressive and often under-detected disease. To address the significant impact of this disease ...

Fine Gael Cllr Damian Boylan led cross-party opposition to the motion, saying Trump and Kennedy had demonstrated 'morally ...